Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas[1].
in vivo
Trastuzumab duocarmazine (SYD985) (3 mg/kg or 10 mg/kg, i.v., once) significantly inhibits tumor growth and prolongs the survival cycle in CB-17 / SCID mice with HER2/neu 3+ cells, with effective in vivo anti-tumor activity[1].
References
[1] Gulden Menderes, et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res. 2017 Oct 1;23(19):5836-5845. DOI:10.1158/1078-0432.CCR-16-2862
